Canakinumab can selectively target IL-1β, a cytokine with a central role in the inflammatory process, and may contribute to modulating disease pathways in SCD (Salinas et al., 2020; Awojoodu et al., 2014). This evidence concerns the gene IL1B and Schnyder corneal dystrophy.